Uric acid as a cardiometabolic risk factor: To be or not to be

Contributions to Nephrology

Volumn 171, Issue , 2011, Pages 62-67

  Kanbay, Mehmet ^a,d   Afsar, Baris ^b   Covic, Adrian ^c  

^a Kayseri Training and Research Hospital   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Alparslan Mahallesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; METABOLIC SYNDROME X; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASES; METABOLIC SYNDROME X; RISK FACTORS; URIC ACID;

EID: 79958132608     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000327160     Document Type: Article

References (56)

1. Nakagawa T, Kang DH, Feig D, et al: Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006;69:1722-1725. (Pubitemid 43739197)
2. Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A: Uric acid in hypertension and renal disease: the chicken or the egg. Blood Purif 2010;30: 288-295.
3. Sautin YY, Johnson RJ: Uric acid: the oxidant- antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008;27:608-619. (Pubitemid 351948591)
4. Kutzing MK, Firestein BL: Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008;324:1-7. (Pubitemid 350294141)
5. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. (Pubitemid 29310011)
6. Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F, Eryonucu B, Covic A, Johnson RJ: Uric acid and pentraxine- 3 levels are independently associated with coronary artery disease risk in patients with stages 2 and 3 kidney disease. Am J Nephrol 2011; 33:325-331.
7. Mitsuhashi H, Yatsuya H, Matsushita K, et al: Uric acid and left ventricular hypertrophy in Japanese men. Circ J 2009;73:667-672.
8. Anker SD, Doehner W, Rauchhaus M, et al: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997. (Pubitemid 36506072)
9. Kanbay M, Sánchez- Lozada LG, Franco M, Madero M, Solak Y, Rodriguez- Iturbe B, Covic A, Johnson RJ: Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant 2011;26:430-437.
10. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ: Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011;33:298-304.
11. Basar N, Sen N, Ozcan F, Erden G, Kanat S, Sokmen E, Isleyen A, Yuzgecer H, Ozlu MF, Yildirimkaya M, Maden O, Covic A, Johnson RJ, Kanbay M: Elevated serum uric acid predicts angiographic impaired reperfusion and one- year mortality in ST- segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Invest Med 2011, E- pub ahead of print.
12. Pacifico L, Cantisani V, Anania C, et al: Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009;160:45-52.
13. Reimann M, Schutte AE, Malan L, Huisman HW, Malan NT: Hyperuricaemia is an independent factor for the metabolic syndrome in a sub- Saharan African population: a factor analysis. Atherosclerosis 2008;197:638-45. (Pubitemid 351419240)
14. Perlstein TS, Gumieniak O, Williams GH, et al: Uric acid and the development of hypertension: the normative aging study. Hypertension 2006;48: 1031-1036. (Pubitemid 44772704)
15. Yoo TW, Sung KC, Shin HS, et al: Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69:928-933.
16. Ford ES, Li C, Cook S, Choi HK: Serum concentration of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007;115:2526-2532. (Pubitemid 46763226)
17. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-1301. (Pubitemid 44354944)
18. Hongo M, Hidaka H, Sakaguchi S, et al: Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J 2010;74: 1570-1577.
19. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-452. (Pubitemid 34563537)
20. Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. Ann Intern Med 2005;143:499-516. (Pubitemid 41379398)
21. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-1821.
22. Nakagawa T, Hu H, Zharikov S, et al: A causal role for uric acid in fructose- induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-F631. (Pubitemid 43724964)
23. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL: Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005;45:34-38. (Pubitemid 40066410)
24. Johnson RJ, Feig DI, Herrera- Acosta J, Kang DH: Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20. (Pubitemid 40066407)
25. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33. (Pubitemid 40066409)
26. Afsar B, Elsurer R, Ozdemir FN, Sezer S: Uric acid and nocturnal nondipping in hypertensive patients with normal renal function. J Nephrol 2008;21:406-411.
27. Rathmann W, Funkhouser E, Dyer AR, Roseman JM: Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8: 250-261. (Pubitemid 28208943)
28. Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303. (Pubitemid 46143005)
29. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure- independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997. (Pubitemid 34654464)
30. Nakagawa T, Mazzali M, Kang DH, et al: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7. (Pubitemid 35316757)
31. Kang DH, Nakagawa T, Feng L, et al: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897. (Pubitemid 35386908)
32. Kosugi T, Nakayama T, Heinig M, Zhang L, et al: Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol 2009;297:F481-F488.
33. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al: Risk factors for development of decreased kidney function in a southeast Asian population: a 12- year cohort study. J Am Soc Nephrol 2005;16:791-799. (Pubitemid 41725116)
34. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44: 642-650. (Pubitemid 39237608)
35. Kanbay M, Ozkara A, Selcoki Y, Isik B, et al: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-1233. (Pubitemid 350193621)
36. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47: 51-59. (Pubitemid 41828266)
37. Goicoechea M, de Vinuesa SG, Verdalles U, et al: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-1393.
38. Sanchez- Lozada LG, Tapia E, Soto V, et al: Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008;108:p69-p78. (Pubitemid 351704308)
39. Tomita M, Mizuno S, Yamanaka H, et al: Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-409.
40. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F: Uric acid as a risk factor for progression of non- diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008;43: 347-352.
41. Madero M, Sarnak MJ, Wang X, et al: Uric acid and long- term outcomes in CKD. Am J Kidney Dis 2009;53: 796-803.
42. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical- caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78: 6858-6862. (Pubitemid 12216861)
43. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular reninangiotensin system. J Hypertens 2008; 26:269-275.
44. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase- mediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol 2007;293:C584-C596. (Pubitemid 47235197)
45. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez- Iturbe B, Herrera- Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41: 1183-1190. (Pubitemid 36706063)
46. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet- derived growth factor A- chain expression. J Biol Chem 1991;266:8604-8608. (Pubitemid 21906552)
47. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821. (Pubitemid 11197783)
48. Sanchez- Lozada LG, Tapia E, Santamaria J, et al: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-247. (Pubitemid 40019245)
49. Sanchez- Lozada LG, Tapia E, Avila- Casado C, et al: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002;283:F1105-F1110. (Pubitemid 35192478)
50. Tsunoda S, Kamide K, Minami J, Kawano Y: Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low- energy diet and an insulin- sensitizing agent. Am J Hypertens 2002;15:697-701. (Pubitemid 34804275)
51. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh- Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein- 1 production in vascular smooth muscle cells via mitogen- activated protein kinase and cyclooxygenase- 2. Hypertension 2003;41:1287-1293. (Pubitemid 36706079)
52. Kanellis J, Kang DH: Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42. (Pubitemid 40128147)
53. Erdei N, Toth A, Pasztor ET, et al: High- fat diet- induced reduction in nitric oxide- dependent arteriolar dilation in rats: role of xanthine oxidase- derived superoxide anion. Am J Physiol Heart Circ Physiol 2006; 291:H2107-H2115.
54. George J, Carr E, Davies J, et al: Highdose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114: 2508-2516. (Pubitemid 44901524)
55. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572. (Pubitemid 37430158)
56. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1): S1-S266.